What is Nuvation Bio's accrued royalties (current)?

Nuvation Bio (NUVB) reported accrued royalties (current) of $1.48M in Q4 2025.

What does accrued royalties (current) mean?

This represents the liability for royalty payments incurred based on sales or licensing agreements that are due for settlement within the next twelve months. It is a critical metric for companies that license intellectual property or technology from third parties. Consistent monitoring ensures the company is meeting its contractual obligations to technology partners.

Nuvation Bio NUVB Accrued Royalties (Current)

Accrued Royalties (Current) at other companies

Jazz PharmaceuticalsJAZZ

——

IncyteINCY

——

Other financials

Income statement

See full

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

See full

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

See full

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation

See full

Market cap$2.1B+150%

Enterprise value$2.03B+154%

P/S14.7×-62.0×

Profitability

See full

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

See full

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrentAndNoncurrent.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's accrued royalties (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nuvation Bio's accrued royalties (current)?: Nuvation Bio (NUVB) reported accrued royalties (current) of $1.48M in Q4 2025.
What does accrued royalties (current) mean?: This represents the liability for royalty payments incurred based on sales or licensing agreements that are due for settlement within the next twelve months. It is a critical metric for companies that license intellectual property or technology from third parties. Consistent monitoring ensures the company is meeting its contractual obligations to technology partners.